Prof. Dr. Hale Başak Çağlar

Hakkında

Özgeçmiş

Mesleki çalışmalarımı Radyasyon Onkolojisi (Radyoterapi) alanında sürdürüyorum. Halen Memorial Göztepe Hastanesi bünyesinde hasta kabul ediyorum.

Eğitim ve deneyim

Eğitim

• 1998 - 2003, İstanbul/Türkiye Marmara Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi ABD
• 1992 - 1998, Ankara/Türkiye Gazi Üniversitesi Tıp Fakültesi Tıp Doktorluğu Eğitimi

Deneyim

• 2026 - Halen, İstanbul/Türkiye Memorial Göztepe Hastanesi Radyasyon Onkolojisi Uzmanı
• 2017 - 2026, Kocaeli/Türkiye Anadolu Sağlık Merkezi Radyasyon Onkolojisi Uzmanı
• 2013 - 2017, İstanbul/Türkiye Medipol Mega Hastanesi Radyasyon Onkolojisi Uzmanı
• 2010 - 2013, İstanbul/Türkiye Acıbadem Maslak Hastanesi Radyasyon Onkolojisi Uzmanı
• 1998 - 2010, İstanbul/Türkiye Marmara Üniversitesi Hastanesi Radyasyon Onkolojisi Uzmanı

Sertifikalar

• Management of Anemia Under Radiochemotherapy (MARCH): An Open Randomized, Multicenter Study of the Effect of NEORECORMON on Treatment Outcome in Patients with Advanced Cervical Cancer Stage IIB-IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) MO16375. International, Multicentric, Co-Investigator.
• Kemik Metastazlı Meme Kanserinde Zoledronik Asit Tedavisi Alan Hastalarda Tam Doz Veya Azaltılmış Doz Radyoterapinin Araştırılması (A Randomized Phase IV exploratory trial comparing full dose radiotherapy versus reduced dose in the management of bone metastasis in breast cancer receiving zoledronic acid) Randomized, phase III, multicentric, CZOL446ETR01, National, Co-Investigator.
• p53 Polimorphisms and Haplotypes in Breast Cancer, Breast Cancer Research Group Study (MEKAG), Co-Investigator
• A Double Blind, Placebo Controlled, Parallel Group, Multicenter, Randomised Phase III Survival Study Comparing ZD1839 (IRESSATM) (250 mg Tablet) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients with Advanced NSCLC Who Have Received One or Two Prior Chemotherapy Regimens and are Refractory or Intolerant to Their Most Recent Regimen, Co-Investigator
• FACT: Anastrozole Monotherapy Versus Maximal Oestrogen Blockade with Anastrozole and Fulvestrant Combination Therapy: An Open Randomized, Comparative

Mesleki üyelikler

• ASTRO (Amerikan Radyasyon Onkolojisi Derneği
• ESTRO (Avrupa Radyoterapi ve Onkoloji Derneği)
• EORTC (Avrupa Kanser Araştırma Birliği)
• Radyocerrahi Derneği
• Türk Akciğer Kanseri Derneği
• Türk Radyasyon Onkolojisi Derneği
• Türk Tabipler Birliği
• Türk Tıbbi Onkoloji Derneği (TTOD)

Bilimsel yayınlar

• Management of Anemia Under Radiochemotherapy (MARCH): An Open Randomized, Multicenter Study of the Effect of NEORECORMON on Treatment Outcome in Patients with Advanced Cervical Cancer Stage IIB-IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) MO16375. International, Multicentric, Co-Investigator.
• 2. Kemik Metastazlı Meme Kanserinde Zoledronik Asit Tedavisi Alan Hastalarda Tam Doz Veya Azaltılmış Doz Radyoterapinin Araştırılması (A Randomized Phase IV exploratory trial comparing full dose radiotherapy versus reduced dose in the management of bone
• metastasis in breast cancer receiving zoledronic acid) Randomized, phase III, multicentric, CZOL446ETR01, National, Co-Investigator.
• 3. p53 Polimorphisms and Haplotypes in Breast Cancer, Breast Cancer Research Group Study (MEKAG), Co-Investigator
• 4. A Double Blind, Placebo Controlled, Parallel Group, Multicenter, Randomised Phase III Survival Study Comparing ZD1839 (IRESSATM) (250 mg Tablet) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients with Advanced NSCLC Who Have Received One or Two Prior Chemotherapy Regimens and are Refractory or Intolerant to Their Most Recent Regimen, Co-Investigator
• 5. FACT: Anastrozole Monotherapy Versus Maximal Oestrogen Blockade with Anastrozole and Fulvestrant Combination Therapy: An Open Randomized, Comparative, Phase III Multicentre Study in Postmenopausal Women with Hormone Receptor Positive Breast Cancer in First Relapse After Primary Treatment of Localised Tumour, Co-Investigator
• 6. Anastrazol Kullanan Erken Evre Meme Kanseri Hastalarında Elektronik Farmakovijilans Çalışması (Anastrazol monotherapy in early stage breast cancer, electronical farmacovigilance study), National, Co-Investigator.
• 7. Rekürren Yüksek Dereceli Glial Tümörlerde Standart Doz Temozolomide Sonrasında Progresyon Gelişiminde Uzamış Temozolomide Şeması Etkinlik Araştırılması (Efficacy of a protracted dose dense temozolamide schedule in patients with progression after standart dose temozolomide for recurrent high grade gliomas), national, Co-Investigator.
• 8. No Radiotherapy Versus Whole Brain Radiotherapy for 1 to 3 Brain Metastases From Solid Tumour After Surgical Resection or Radiosurgery, A Randomized Phase III Trial, EORTC Protocol 22952-26001, International, Multicentric, Co-Investigator.
• 9. -EULINT1. International Prophylactic Cranial Irradiation Trial. A Multicenter Randomized Trial of High Versus Standard Doses of Prophylactic Cranial Irradiation in Limited Small Cell Lung Cancer Complete Responders, EORTC Protocol 22003-08004, International, Multicentric study, Co-Investigator.
• 10. AMAROS After Mapping of the Axilla: Radiotherapy or Surgery, EORTC protocol 10981-22023, International, Multicentric study, Co-Investigator.
• 11. SUPREMO A Phase III Randomized Trial to Assess the Role of Adjuvant Chest Wall Irradiation in “Intermediate Risk” Operable Breast Cancer Following Mastectomy, EORTC Protocol 22051-10052, International, Multicentric study, Co-Investigator.
• 12. Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. EORTC Protocol 26053-22054. International, Multicentric study, Co-Investigator.
• 13. Adjuvant Postoperative High-dose Radiotherapy for Atypical and Malignant Meningioma: A Phase-II and Observation Study. EORTC protocol 22042-26042 International, Multicentric study, Co-Investigator.
• 14. Meme Kanseri Tanısı ile Takip Edilen Hastalarda Kemik Metastazının Görülme Sıklığını, Tanı Yöntemlerini ve Tedavi Yaklaşımlarını Değerlendiren Gözlem Çalışması, ZO-SAFE. (The frequency, diagnostic tools used and treatment modalities of bone metastatic breast cancer: an observation study ZO-SAFE). Protokol no: CZOL446ETR02, National, Multicentric study, Co-Investigator.
• 15. A Multinational, Randomized, Double-blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-line Docetaxel After Failure of one Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). VITAL EFC10261. International, Multicentric study, Co-Investigator.
• 16. Hormon Reseptörü Pozitif Opere Postmenopozal Meme Kanserli Hastaların Erken Adjuvan Tedavisinde Aromataz İnhibitörü Kullanımının Güvenliliği ve Nüks Paterni Üzerine Etkileri, ERADA. (Aromatase inhibitors in the adjuvant treatment of hormone receptor positive breast cancer: Implications on safety on recurrence patterns, ERADA). Protokol no: CFEM345DTR002. National, Multicentric study, Primary Investigator.
• 17. Akciğer Kanseri Nedeniyle Eş Zamanlı Kemoradyoterapi + Oral Glutamin Uygulanan Hastalarda Yaşam Kalitesi Değerlendirmesi. (Concuurent chemoradiation + oral glutamine in locally advanced lung cancer: a quality of life study). Primary Investigator.
• Publıcatıons
• A. International journals :
• A1. Yumuk PF, Abacioglu U, Caglar H, Gumus M, Sengoz M, Turhal NS. Outcome of Rectal and Sigmoid Carcinoma Patients Receiving Adjuvant Chemoradiotherapy in Marmara University Hospital. J. Chemotherapy, 15(6), 603-606, (2003).
• A2. Gumus M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar H, Sengoz M, Turhal S. What is the optimal number of lymph nodes dissected in colorectal cancer surgery? Tumori (91:168-172, 2005)
• A3. Abacioglu U, Yumuk PF, Çağlar H, Sengoz M, Turhal NS. Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer. BMC Cancer, Vol 5:71, 2005.
• A4. Caglar H, Allen AM. Intensity Modulated Radiotherapy for Head and Neck Cancer. Clinical Advances in Hematology & Oncology. 2007 Jun;5(6):425-31.
• A5. Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, Akgul AG, Evman S, Yuksel M. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol. 2008 May;3(5):499-504.
• A6. Caglar HB, Tishler RB, Othus M, Burke E, Li Y; Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM. Dose to Larynx Predicts for Swallowing
• Complications After Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys. November 2008;72(4):1110-1118.
• A7. Demiral AN, Alicikus ZA, Ugur VI, Karadogan I, Yoney A, Andrieu MN, Yalman D, Pak Y, Aksu G, Ozyigit G, Ozkan L, Kilciksiz S, Koca S, Caloglu M, Yavuz AA, Caglar HB, Beyzadeoglu M, Igdem S, Serin M, Kaplan B, et al. Patterns of Care for Lung Cancer in Radiation Oncology Departments of Turkey. Int J Radiat Oncol Biol Phys. 72(5):1530-1537, May 2008.
• A8. Akkiprik M, Sonmez O, Gulluoglu BM, Caglar HB, Kaya H, Demirkalem P, Abacioglu U, Sengoz M, Sav A, Ozer A. Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer. Pathology and Oncology Research, (Epub ahead of print), (2008).
• A9. Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM. Outcomes of Patients with Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery. Cancer, 2009 Sep 23;115(18):4156-4166.
• A10. Basaran G, Devrim C, Caglar HB, Gulluoglu B, Kaya H, Seber S, Korkmaz T, Telli F, Kocak M, Dane F, Yumuk FP, Turhal SN. Clinical outcome of breast cancer patients with N3a ( /=10 positive lymph nodes) disease: has it changed over years? Med Oncol. 2011 Sep;28(3):726-32.
• A11 Abacioglu U, Caglar H, Atasoy BM, Abdulloev T, Akgun Z, Kilic T. Gamma knife radiosurgery in non small cell lung cancer patients with brain metastases: treatment results and prognostic factors. J BUON. 2010 Apr-Jun;15(2):274-80.
• A12 Alexander BM, Othus M, Caglar HB, Allen AM. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1381-7
• A13 Caglar HB, Othus M, Allen AM. Esophagus in-field: a new predictor for esophagitis. Radiother Oncol. 2010 Oct;97(1):48-53.
• A14 Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neurooncol. 2010 Sep 29. [Epub ahead of print].
• A15 Atasoy BM, Dane F, Uçüncü Kefelı A, Cağlar H, Cıngı A, Turhal NS, Abacioğlu U, Yeğen C. Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer. Turk J Gastroenterol. 2011 Feb;22(1):60-4.
• A16 Allen AM, Albert M, Caglar HB, Zygmanski P, Soto R, Killoran J, Sun Y. Can Hyperpolarized Helium MRI add to radiation planning and follow-up in lung cancer? J Appl Clin Med Phys. 2011 Jan 31;12(2):3357.
• A17 Midi A, Belirgen M, Caglar H, Sav A. Investigation of The Effect of Radiotherapy on The Proliferative Index (Ki-67) in Recurring Diffuse Glial Tumors. Journal of Neurological Sciences (Turkish), 28(1).
• A18 Schick U, Bolukbasi Y, Thariat J, Abdah-Bortnyak R, Kuten A, Igdem S, Caglar H, Ozsaran Z, Lössl. Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e757-63.
• A19 Ozyar E, Caglar HB, Atalar B. In regard to Zhou et al "Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis" (Int J Radiat Oncol Biol Phys 2012;82:e359-e365). Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):482-3.

Konuşulan diller

Çalışma yerleri 1